PT  - JOURNAL ARTICLE
AU  - C. McNamara
AU  - G. Sugrue
AU  - B. Murray
AU  - P.J. MacMahon
TI  - Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 1—Mechanisms, Efficacy, and Safety
AID  - 10.3174/ajnr.A5147
DP  - 2017 Apr 13
TA  - American Journal of Neuroradiology
4099  - http://www.ajnr.org/content/early/2017/04/13/ajnr.A5147.short
4100  - http://www.ajnr.org/content/early/2017/04/13/ajnr.A5147.full
AB  - SUMMARY: Imaging for the diagnosis and follow-up of patients with suspected or confirmed multiple sclerosis is a common scenario for many general radiologists and subspecialty neuroradiologists. The field of MS therapeutics has rapidly evolved with multiple new agents now being used in routine clinical practice. To provide an informed opinion in discussions concerning newer MS agents, radiologists must have a working understanding of the strengths and limitations of the various novel therapies. The role of imaging in MS has advanced beyond monitoring and surveillance of disease activity to include treatment complications. An understanding of the new generation of MS drugs in conjunction with the key role that MR imaging plays in the detection of disease progression, opportunistic infections, and drug-related adverse events is of vital importance to the radiologist and clinical physician alike. Radiologists are in a unique position to detect many of the described complications well in advance of clinical symptoms. Part 1 of this review outlines recent developments in the treatment of MS and discusses the published clinical data on the efficacy and safety of the currently approved and emerging therapies in this condition as they apply to the radiologist. Part 2 will cover pharmacovigilance and the role the neuroradiologist plays in monitoring patients for signs of opportunistic infection and/or disease progression.AbbreviationsIFNβinterferon βNTZnatalizumabPMLprogressive multifocal leukoencephalopathyRRMSrelapsing-remitting MS